93 related articles for article (PubMed ID: 699954)
1. Immune responses to weakly immunogenic virally induced tumors. II. Suppressive effects of the in vivo carried tumor YAC.
Devens B; Galili N; Deutsch O; Naor D; Klein E
Eur J Immunol; 1978 Aug; 8(8):573-8. PubMed ID: 699954
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to weakly immunogenic virally induced tumors. I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross-reactive tumor.
Galili N; Devens B; Naor D; Becker S; Klein E
Eur J Immunol; 1978 Jan; 8(1):17-22. PubMed ID: 639838
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to weakly immunogenic virally induced tumors. III. Genetically unrestricted cytolysis of allogeneic tumor target cells.
Devens B; Naor D
J Immunol; 1979 Apr; 122(4):1397-401. PubMed ID: 312839
[TBL] [Abstract][Full Text] [Related]
4. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VII. Kinetic studies on various parameters of effects induced with suppressor cells.
Deutsch O; Devens B; Naor D
Isr J Med Sci; 1980 Jul; 16(7):530-7. PubMed ID: 6447122
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VIII. Characterization of suppressor cells.
Deutsch O; Devens B; Naor D
Isr J Med Sci; 1980 Jul; 16(7):538-44. PubMed ID: 6447123
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).
Kedar E; Unger E; Galili N; Klein G; Asjo B; Bonavida B; Naor D
Prog Clin Biol Res; 1976; 9():109-21. PubMed ID: 1030796
[TBL] [Abstract][Full Text] [Related]
7. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
[TBL] [Abstract][Full Text] [Related]
8. Immune response to weakly immunogenic virally induced tumors. IX. Mice injected with the in vitro variant of YAC tumor (YAC-1) resist lethal doses of the tumorigenic YAC cells.
Devens B; Deutsch O; Avraham Y; Naor D
Immunobiology; 1981; 159(4-5):432-43. PubMed ID: 7287048
[TBL] [Abstract][Full Text] [Related]
9. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to weakly immunogenic virally induced tumors. VI. Comparison of the immune response of the hybrid to the immune responses of the parents reveals "hybrid responsiveness" effect.
Devens B; Naor D
J Immunol; 1980 Sep; 125(3):988-94. PubMed ID: 6447725
[No Abstract] [Full Text] [Related]
11. The immune response to Moloney murine leukemia virus-induced tumors: induction of cytolytic T lymphocytes specific for both viral and tumor-associated antigens.
Flyer DC; Burakoff SJ; Faller DV
J Immunol; 1986 Dec; 137(12):3968-72. PubMed ID: 3491152
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. II. Stimulation of syngeneic antitumor cell-mediated immune responses by subcellular fractions and molecular species of the Rauscher-virus-induced RBL5 tumor.
Kobrin BJ; Naor D; Klein BY
J Immunol; 1981 May; 126(5):1874-82. PubMed ID: 6260859
[No Abstract] [Full Text] [Related]
13. Mechanisms of leukemogenesis. I. Generation of autoreactive lymphocytes in response to a murine leukemia virus.
Schenk PJ; Howe ML
J Immunol; 1979 May; 122(5):1874-80. PubMed ID: 221580
[TBL] [Abstract][Full Text] [Related]
14. In vitro studies of cell-mediated immunity to Moloney murine leukemia virus and Moloney leukemia-associated surface antigens.
Ng AK; Ames RS; McIntire RK; Herberman RB
Cancer Res; 1979 Dec; 39(12):4887-93. PubMed ID: 387218
[TBL] [Abstract][Full Text] [Related]
15. Studies on the susceptibility of C57BL-6 mice to Rauscher virus. 3. Kinetics of humoral antibody response to cell-surface antigens in neonatally inoculated mice.
Ishimoto A; Ito Y
J Natl Cancer Inst; 1973 Aug; 51(2):553-64. PubMed ID: 4765372
[No Abstract] [Full Text] [Related]
16. Presence of antibody against mouse fetal antigen in the sera from C57BL-6 mice immunized with Rauscher leukemia.
Ishimoto A; Ito Y
Cancer Res; 1972 Nov; 32(11):2332-7. PubMed ID: 4343227
[No Abstract] [Full Text] [Related]
17. Cell-mediated immunity to Friend virus-induced leukemia. III. Characteristics of secondary cell-mediated cytotoxic response.
Ting CC; Kirchner H; Rodrigues D; Park JY; Herberman RB
J Immunol; 1976 Jan; 116(1):244-52. PubMed ID: 54388
[TBL] [Abstract][Full Text] [Related]
18. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.
Plata F; Cerottini JC; Brunner KT
Eur J Immunol; 1975 Apr; 5(4):227-33. PubMed ID: 185057
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
[TBL] [Abstract][Full Text] [Related]
20. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
